Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.

BACKGROUND & AIMS Recent population-based studies have shown a low risk of esophageal adenocarcinoma (EAC) in patients with nondysplastic Barrett's esophagus (NDBE). We evaluated whether persistence of NDBE over multiple consecutive surveillance endoscopic examinations could be used in risk stratification of patients with Barrett's esophagus (BE). METHODS We performed a multicenter outcomes study of a large cohort of patients with BE. Based on the number of consecutive surveillance endoscopies showing NDBE, we identified 5 groups of patients. Patients in group 1 were found to have NDBE at their first esophagogastroduodenoscopy (EGD). Patients in group 2 were found to have NDBE on their first 2 consecutive EGDs. Similarly, patients in groups 3, 4, and 5 were found to have NDBE on 3, 4, and 5 consecutive surveillance EGDs. A logistic regression model was built to determine whether persistence of NDBE independently protected against development of cancer. RESULTS Of a total of 3515 patients with BE, 1401 patients met the inclusion criteria (93.3% white; 87.5% men; median age, 60 ±17 years). The median follow-up period was 5 ± 3.9 years (7846 patient-years). The annual risk of EAC in groups 1 to 5 was 0.32%, 0.27%, 0.16%, 0.2%, and 0.11%, respectively (P for trend = .03). After adjusting for age, sex, and length of BE, persistence of NDBE, based on multiple surveillance endoscopies, was associated with a gradually lower likelihood of progression to EAC. CONCLUSIONS Persistence of NDBE over several endoscopic examinations identifies patients who are at low risk for development of EAC. These findings support lengthening surveillance intervals or discontinuing surveillance of patients with persistent NDBE.

[1]  H. El‐Serag,et al.  Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? , 2003, American Journal of Gastroenterology.

[2]  H. Welch,et al.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. , 2005, Journal of the National Cancer Institute.

[3]  J. Goldblum,et al.  Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. , 2011, Gastroenterology.

[4]  M. Canto,et al.  Predicting Neoplastic Progression in Barrett's Esophagus. , 2010, Annals of gastroenterology & hepatology.

[5]  R. Playford New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus , 2006, Gut.

[6]  Prateek Sharma,et al.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus. , 2011, Gastroenterology.

[7]  K. Behrns,et al.  Incidence of Adenocarcinoma among Patients with Barrett's Esophagus , 2012 .

[8]  Prateek Sharma,et al.  Clinical practice. Barrett's esophagus. , 2009, The New England journal of medicine.

[9]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[10]  D. Sautereau,et al.  French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett’s esophagus , 2007, Endoscopy.

[11]  E. Kuipers,et al.  Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study , 2010, Gut.

[12]  Prateek Sharma,et al.  American Gastroenterological Association technical review on the management of Barrett's esophagus. , 2011, Gastroenterology.

[13]  R. Sampliner,et al.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.

[14]  Douglas K Rex,et al.  Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. , 2012, Gastroenterology.

[15]  H. El‐Serag,et al.  Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? , 2003 .

[16]  E. Kuipers,et al.  Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Robert H Fletcher,et al.  Guidelines for Colonoscopy Surveillance after Polypectomy: A Consensus Update by the US Multi‐Society Task Force on Colorectal Cancer and the American Cancer Society * , † , 2006, Gastroenterology.

[18]  Amy Wang,et al.  M1104 Predicting High-Grade Dysplasia (HGD) and Esophageal Adenocarcinoma (EAC) in Patients With Non-Dysplastic Barrett's Esophagus (BE): Results From a Large, Multicenter Cohort Study , 2010 .

[19]  R. Sampliner,et al.  Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus , 2002, American Journal of Gastroenterology.

[20]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[21]  D. Faigel,et al.  ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. , 2006, Gastrointestinal endoscopy.

[22]  J K Greenson,et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. , 2001, Human pathology.

[23]  A. Rastogi,et al.  Feasibility of MicroRNAs as Biomarkers for Barrett's Esophagus Progression: A Pilot Cross-Sectional, Phase 2 Biomarker Study , 2011, The American Journal of Gastroenterology.

[24]  A. Gavin,et al.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. , 2011, Journal of the National Cancer Institute.

[25]  D. Ransohoff,et al.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.

[26]  Amy Wang,et al.  Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  M F Dixon,et al.  The Vienna classification of gastrointestinal epithelial neoplasia , 2000, Gut.